Clinical Trial

Innate Immunity in Allergic Asthma

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 6, 2024 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to determine whether a potential type 2 signature, obtained through stimulation of cell lines with various allergens in vitro, correlates with an allergic or asthmatic disease state ex vivo. This type 2 signature will be multi-hierarchical in nature and will be comprised cell surface receptor expression, pathway activation, and gene upregulation.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-09-28; most recent amendment 2024-12-03.
Trial Details
NCT Number NCT06068335
Lead Sponsor University of Central Florida
Conditions Asthma
Enrollment 100 participants
Start Date 2021-10-18
Primary Completion 2025-06 (estimated)
Study Completion 2025-06 (estimated)
Updated on ClinicalTrials.gov 2024-12-06